Fundz

Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer

PUBLIC · TRDAOct 21, 2026

Position

Chief People Officer

Company

Entrada Therapeutics, Inc.

Linea Aspesi
BostonHealthcareBiotechnology Research

Description

Entrada Therapeutics has announced the appointment of Linea Aspesi as Chief People Officer to help scale the people and organization for its next phase of growth. Aspesi brings over twenty years of experience in transforming organizational culture and driving employee engagement.

Who to call at Entrada Therapeutics, Inc., and when

A new leader at Entrada Therapeutics, Inc. brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Entrada Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Entrada Therapeutics, Inc., from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Entrada Therapeutics, Inc.

Location

6 TIDE STREET

Boston, Massachusetts, United States

About

Headquartered in Boston’s Seaport community, Entrada Therapeutics is a growing biopharmaceutical company innovating to transform the treatment of devastating diseases through intracellular therapeutics. We’re establishing a new class of medicines, Endosomal Escape Vehicles (EEV™)-therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable. Our EEV™ therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through our proprietary, highly versatile, and modular EEV™ Platform, we are building a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, immunological, ocular and metabolic diseases, among others. Our lead oligonucleotide programs include ENTR-601-44 and ENTR-601-45 for the potential treatment of people living with Duchenne who are exon 44 and 45 skipping amenable, respectively, as well as our partnered candidate ENTR-701 targeting myotonic dystrophy type 1 (DM1). For more information about Entrada, please visit www.entradatx.com.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Entrada Therapeutics, Inc. changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Nathan
Likely contact at this company
••••••••@••••••••

See Nathan's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Entrada Therapeutics, Inc.'s next move

Learn about Strategic plan

Entrada Therapeutics, Inc. changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.